Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) and biopharmaceutical company Zai Lab Limited (Nasdaq:ZLAB) (HKEX:9688) announced on Monday that the Chinese National Medical Products Administration (NMPA) has approved VYVGART Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
VYVGART Hytrulo is the first and only NMPA-approved treatment for CIDP in China. The approval was based on positive results from the ADHERE clinical trial, which demonstrated the drug's efficacy and safety in Chinese patients.
Zai Lab holds exclusive rights to develop and commercialise efgartigimod in mainland China, Hong Kong, Macau and Taiwan.
VYVGART Hytrulo is now approved in China for both generalised myasthenia gravis (gMG) and CIDP.
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Vanda Pharmaceuticals receives Orphan Drug Designation from FDA for VGT-1849A
Hansa Biopharma reports positive Phase 2 imlifidase results
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
GSK's Submission for Nucala (mepolizumab) in COPD accepted by US FDA
Evommune presents positive data from EVO756 first-in-human proof-of-concept trial
Rigel Pharmaceuticals' R289 granted US FDA Fast Track designation
Revelation Biosciences secures FDA acceptance for Gemini IND, Phase 1b CKD study set for 2025
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein